FEATURED EDITORIAL
With the right biology, a single mechanism can open multiple clinically meaningful avenues for oncology drug development. Step Pharma CEO discusses their clinical development programs for oncology.
- Redesigning Oncology Trials Around Tumor Vulnerability: The Rise of WEE1 And DDR Strategies
- Targeting GRIN Genes In Drug Development To Treat Neurodevelopment Disorders
- Can America's Retreat On mRNA Be Europe's Opportunity?
- The OBBBA: Biopharmas Unlock R&D Expensing, Global Tax Efficiencies
- AI Plus The Scientific Method Might Reinvent Drug Discovery
- Developing Interleukin-2 For Cell Therapies: Key Considerations
- Unlocking The Pharmacological Potential Of Antibodies
FEATURED APPLICATION CONTENT
-
Characterizing the PROTAC hook effect is crucial for selecting candidates with enhanced cooperativity. Gain confidence with flexible, in-solution affinity measurements that reveal key biophysical parameters and align with established three-component binding models.
-
Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.
-
Explore how process intensification can revolutionize monoclonal antibody manufacturing to boost productivity, cut costs, and enhance sustainability with scalable strategies and real-world results.
-
See how the recently described cell line development paradigm shift, enabled by the Leap-In transposon platform, can extend to the development of bispecific monoclonal antibody-producing cell substrates.
-
As regulations tighten, biomanufacturers are adopting single-use tech to boost compliance, reduce labor, and streamline fill-finish operations from the ground up.
-
Learn how researchers optimized CHO cell culture to boost IgG1 titer to 5.8 g/L and improve viability, which cut development time from 14 days to 12 while enhancing productivity.
-
Learn how a comprehensive, variant-aware screening workflow for therapeutic gene editing can identify and nominate the most favorable guide RNAs for clinical development.
-
Optimizing input parameters like DBC, flow rate, and resin durability is key to boosting productivity in downstream bioprocessing. Discover how to tailor resin choices to meet your specific process requirements.
-
Accelerate drug discovery by leveraging transiently transfected assay-ready cells. This method improves assay sensitivity and reduces variability for GPCRs.
-
Learn about a novel cell-based assay that can advance ubiquitin ligase drug discovery. This high-throughput method simplifies assay development, saving time and resources.
-
High-throughput screening of KCNQ2 ion channel variants provides insights into epilepsy and treatment responses. This validated method supports rapid characterization for precision medicine.
-
Navigate the FDA's gene therapy guidelines with advanced risk assessment strategies. Optimize gene editing and ensure regulatory alignment for safer, more effective therapies.
FEATURED NEWS HEADLINES
- Queen Mary Trials New Approach To Drug Development For Rare Diseases
- GNQ Insilico Launches Revolutionary AI-Driven Assessment Platform To Transform Precision Medicine And Drug Development
- Symeres Acquires DGr Pharma To Enhance Regulatory Expertise And Broaden Its Biopharma Capabilities
- Lilly Launches TuneLab Platform To Give Biotechnology Companies Access To AI-Enabled Drug Discovery Models Built Through Over $1B In Research Investment
- XtalPi AI Drug Discovery Collaboration Reaches Milestone As PharmaEngine's Novel PRMT5 Inhibitor PEP08 Receives Clinical Trial Approvals
- insitro Partners With Lilly To Build First-In-Kind Machine Learning Models To Advance Small Molecule Drug Discovery
- Teva's Emrusolmin Granted U.S. FDA Fast Track Designation For Treatment Of Multiple System Atrophy
- New UMaine Research Could Help Lower Prescription Drug Costs
- Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development
- Karmanos Researcher Co-Discovered Compound, Led To First FDA-Approved Therapy For Rare Brain Cancer
ARCHIVED NEWSLETTER
- 09.09.25 -- TYK2 Inhibition Emerges As A Next-Gen Strategy To Treat PsA
- 09.04.25 -- Learn how to enhance productivity in your monoclonal antibody (mAb) capture process
- 09.02.25 -- From Undruggable To Druggable: The Science Reshaping Small Molecule Discovery
- 08.28.25 -- Find Small Molecule CDMOs With Available Capacity
- 08.27.25 -- Learn From Cell & Gene Therapy CDMOs With Available Capacity